Erik A Lachapelle
Overview
Explore the profile of Erik A Lachapelle including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
52
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tuttle J, Allais C, Allerton C, Anderson A, Arcari J, Aschenbrenner L, et al.
J Med Chem
. 2025 Feb;
PMID: 40019854
In early 2020, severe acute respiratory syndrome coronavirus 2 (SARS CoV-2) infections leading to COVID-19 disease reached a global level leading to the World Health Organization (WHO) declaration of a...
2.
Garnsey M, Wang Y, Edmonds D, Sammons M, Reidich B, Ahn Y, et al.
Nat Commun
. 2025 Jan;
16(1):297.
PMID: 39746932
Several hydroxysteroid dehydrogenase 17-beta 13 variants have previously been identified as protective against metabolic dysfunction-associated steatohepatitis (MASH) fibrosis, ballooning and inflammation, and as such this target holds significant therapeutic potential....
3.
Butler C, Popiolek M, McAllister L, Lachapelle E, Kramer M, Beck E, et al.
J Med Chem
. 2024 Jun;
67(13):10831-10847.
PMID: 38888621
Selective activation of the M muscarinic acetylcholine receptor subtype offers a novel strategy for the treatment of psychosis in multiple neurological disorders. Although the development of traditional muscarinic activators has...
4.
Wang Y, Bi C, Kawamata Y, Grant L, Samp L, Richardson P, et al.
Nat Chem
. 2024 May;
16(9):1539-1545.
PMID: 38769366
Electrophilic halogenation is a widely used tool employed by medicinal chemists to either pre-functionalize molecules for further diversity or incorporate a halogen atom into drugs or drug-like compounds to solve...
5.
Bai G, OConnell T, Brodney M, Butler C, Czabaniuk L, Gilbert A, et al.
ACS Med Chem Lett
. 2021 Oct;
12(10):1585-1588.
PMID: 34676040
The ring strain present in azetidines can lead to undesired stability issues. Herein, we described a series of N-substituted azetidines which undergo an acid-mediated intramolecular ring-opening decomposition via nucleophilic attack...
6.
Dutra J, Foley T, Huang Z, Fisher E, Lachapelle E, Mahapatra S, et al.
Chembiochem
. 2021 Jan;
22(10):1769-1774.
PMID: 33491295
Herein, we report a general and simplified synthesis of fluorophosphonates directly from p-nitrophenylphosphonates. This FP on-demand reaction is mediated by a commercially available polymer-supported fluoride reagent that produces a variety...
7.
Yang Q, Lachapelle E, Kablaoui N, Webb D, Popiolek M, Grimwood S, et al.
ACS Med Chem Lett
. 2019 Jun;
10(6):941-948.
PMID: 31223452
It has been hypothesized that selective muscarinic acetylcholine receptor (mAChR) M4 subtype activation could provide therapeutic benefits to a number of neurological disorders while minimizing unwanted cholinergic side effects observed...
8.
Helal C, Arnold E, Boyden T, Chang C, Chappie T, Fennell K, et al.
J Med Chem
. 2018 Apr;
61(8):3753.
PMID: 29624389
No abstract available.
9.
ONeill B, Beck E, Butler C, Nolan C, Gonzales C, Zhang L, et al.
J Med Chem
. 2018 Apr;
61(10):4476-4504.
PMID: 29613789
A major challenge in the development of β-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitors for the treatment of Alzheimer's disease is the alignment of potency, drug-like properties, and...
10.
Zhang L, Chen L, Beck E, Chappie T, Coelho R, Doran S, et al.
J Med Chem
. 2017 Sep;
60(20):8538-8551.
PMID: 28957634
As part of our effort in identifying phosphodiesterase (PDE) 4B-preferring inhibitors for the treatment of central nervous system (CNS) disorders, we sought to identify a positron emission tomography (PET) ligand...